Sunday 18 October 2026
Export AFIB’s income statement to Excel — free account
Acutus Medical, Inc.
AFIB Healthcare Medical Devices
In the quarter to December 2024, revenue grew 204.2%, EPS grew 95.9% and free cash flow grew 76.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow AFIB
| Dec '24 | Sep '24 | Jun '24 | Mar '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.09 | 0.16 | 0.07 | 0.56 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.44) | (0.64) | (0.13) | (0.32) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.01 | 1.44 | 1.62 | 2.10 | |
EV/EBITDA |
10.86 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.64) | (0.49) | (0.35) | (0.31) | |
EV/FCF |
(0.64) | (0.49) | (0.36) | (0.31) | |
Quick Ratio |
1.76 | 1.54 | 1.82 | 2.81 | |
Current Ratio |
2.06 | 1.85 | 2.30 | 3.48 | |
Net Debt/EBITDA |
41.31 | 21.62 | 24.91 | (59.39) | |
Debt/Assets |
113.69% | 100.58% | 90.73% | 83.09% | |
Debt/Equity |
(2.81) | (3.14) | (6.70) | (8.61) | |
Asset Turnover |
0.49 | 0.26 | 0.18 | 0.12 | |
Operating CF/Net income |
2.89 | 0.66 | 7.63 | 10.45 | |
Capex/Depreciation |
0.05 | (0.01) | (0.08) | (0.32) | |
Interest Coverage |
(0.20) | 0.35 | 0.20 | (0.39) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
35.80% | 44.02% | 53.91% | 92.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 2.43% | 3.13% | 5.57% | |
Graham Net Nets |
(8.21) | (6.42) | (13.26) | (2.11) | |
Graham Number |
1.69 | 3.34 | 2.48 | 2.64 | |
Earnings Yield |
(545.33%) | (1,794.37%) | (5,651.67%) | (1,275.28%) | |
Free Cash Flow Yield |
(1,778.87%) | (1,879.05%) | (6,225.47%) | (1,208.96%) | |
Revenue per Share |
0.24 | 0.18 | 0.14 | 0.12 | |
Operating CF per Share |
(0.14) | (0.12) | (0.23) | (0.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.12) | (0.24) | (0.57) | |
Cash per Share |
0.47 | 0.42 | 0.45 | 0.67 | |
Shareholders Equity per Share |
(0.39) | (0.35) | (0.16) | (0.14) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.39) | (0.35) | (0.16) | (0.14) | |
Free Cash Flow |
(4.02) | (3.70) | (7.01) | (17.03) | |
Working Capital |
13.14 | 12.49 | 16.08 | 24.53 | |
Capital Expenditures |
0.04 | 0.00 | (0.04) | (0.10) | |
Net Current Asset Value |
(14.66) | (15.31) | (11.82) | (11.28) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.62 | 9.46 | 8.45 | 6.55 | |
Average Payables |
2.02 | 3.23 | 3.59 | 4.37 | |
Average Inventory |
3.03 | 9.96 | 10.44 | 10.41 | |
Average Assets |
41.30 | 58.45 | 67.88 | 78.83 | |
Average Common Equity |
(6.24) | 10.70 | 19.47 | 28.22 |
Columns are period end dates